GSK plc
GLAXF
$20.00
$0.653.36%
Weiss Ratings | GLAXF - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
Rating | ||||
Reward Index | Good | |||
Risk Index | Weak | |||
Risk Grade | D | |||
Reward Grade | B- | |||
Rating Factors | GLAXF - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
Dividend Index | Good | |||
Growth Index | Fair | |||
Efficiency Index | Excellent | |||
Solvency Index | Good | |||
Total Return Index | Weak | |||
Volatility Index | Weak | |||
Beta / Standard Deviation | GLAXF - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
Beta | 0.15 | |||
Price History | GLAXF - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
7-Day Total Return | 9.77% | |||
30-Day Total Return | 21.40% | |||
60-Day Total Return | 12.03% | |||
90-Day Total Return | 6.35% | |||
Year to Date Total Return | 21.80% | |||
1-Year Total Return | -3.02% | |||
2-Year Total Return | 22.41% | |||
3-Year Total Return | 5.51% | |||
5-Year Total Return | 3.38% | |||
52-Week High % Change | -15.87% | |||
52-Week Low % Change | 23.41% | |||
Price | GLAXF - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
52-Week High Price | $23.00 | |||
52-Week Low Price | $15.68 | |||
52-Week Low Price (Date) | Jan 13, 2025 | |||
52-Week High Price (Date) | May 22, 2024 | |||
Valuation | GLAXF - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
Market Cap | 80.77B | |||
Enterprise Value | 96.37B | |||
Price/Earnings (TTM) | 24.43 | |||
Earnings Per Share (TTM) | 0.79 | |||
Earnings Per Share Growth | -47.11% | |||
Price/Earnings To Growth | -- | |||
Price/Sales (TTM) | 2.00 | |||
Price/Book (Q) | 4.61 | |||
Enterprise Value/Revenue (TTM) | 2.40 | |||
Price | $20.00 | |||
Enterprise Value/EBITDA (TTM) | 8.60 | |||
Enterprise Value/EBIT | 12.37 | |||
Market Cap Category | Large Cap | |||
Dividends and Shares | GLAXF - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
Shares Outstanding | 4.15B | |||
Dividend Yield | 3.15% | |||
Div. Per Share (Most Recent) | $0.16 | |||
Dividend Per Share (TTM) | $0.61 | |||
Payout Ratio (TTM) | 95.77% | |||
Dividend Per Share (Most Recent) | $0.16 | |||
Company Info | GLAXF - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
Phone Number | 44 20 8047 5000 | |||
Address | -- | |||
Website | www.gsk.com | |||
Country | United Kingdom | |||
Year Founded | 1715 | |||
Profitability | GLAXF - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
Operating Margin (TTM) | 19.42% | |||
Profit Margin | 8.13% | |||
Management Effectiveness | GLAXF - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
Return on Assets | 6.51% | |||
Return on Equity | 22.90% | |||
Income Statement | GLAXF - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
Revenue (TTM) | 40.10B | |||
Total Revenue (TTM) | 40.10B | |||
Revenue Per Share | $9.68 | |||
Gross Profit (TTM) | 28.80B | |||
EBITDA (TTM) | 11.21B | |||
EBIT (TTM) | 7.79B | |||
Net Income (TTM) | 3.26B | |||
Net Income Avl. to Common (TTM) | 3.26B | |||
Total Revenue Growth (Q YOY) | 3.93% | |||
Earnings Growth (Q YOY) | 29.78% | |||
EPS Diluted (TTM) | 0.79 | |||
EPS Diluted Growth (Q YOY) | 20.94% | |||
Balance Sheet | GLAXF - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
Cash and Short-Term Inv. (Q) | 5.42B | |||
Cash Per Share (Q) | $1.31 | |||
Total Current Assets (Q) | 21.28B | |||
Total Preferred Equity (Q) | -- | |||
Total Equity (Q) | 16.38B | |||
Current Ratio (Q) | 0.783 | |||
Book Value Per Share (Q) | $4.19 | |||
Total Assets (Q) | 74.44B | |||
Total Current Liabilities (Q) | 27.16B | |||
Total Debt (Q) | 21.27B | |||
Total Liabilities (Q) | 58.06B | |||
Total Common Equity (Q) | 17.12B | |||
Cash Flow | GLAXF - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
Cash from Investing (TTM) | -1.60B | |||
Cash from Financing (TTM) | -6.03B | |||
Net Change in Cash (TTM) | 698.87M | |||
Levered Free Cash Flow (TTM) | 6.26B | |||
Cash from Operations (TTM) | 8.40B | |||